Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]

48396 reported adverse events

Drugs of this class: LEDIPASVIR AND SOFOSBUVIR VELPATASVIR AND SOFOSBUVIR SOFOSBUVIR SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR

These side effects are most commonly reported by patients taking drugs of the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC] class:

# Side effect Count
0 FATIGUE 8761
1 HEADACHE 7256
2 NAUSEA 3560
3 DRUG INEFFECTIVE 3287
4 HEPATITIS C 2774
5 INSOMNIA 2154
6 DIARRHOEA 2053
7 ANAEMIA 1514
8 OFF LABEL USE 1486
9 TREATMENT FAILURE 1400
See all common reactions for Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]

Drugs of the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HEPATIC HYDROTHORAX 28 0.4912
1 GENOTYPE DRUG RESISTANCE TEST POSITIVE 388 0.4455
2 HEPATITIS C RNA POSITIVE 69 0.4423
3 HEPATIC CANCER RECURRENT 83 0.3934
4 HEPATITIS C VIRUS TEST POSITIVE 178 0.3633
5 HEPATITIS C RNA 11 0.3143
6 HEPATITIS C 2774 0.2587
7 REMISSION NOT ACHIEVED 98 0.2450
8 HEPATOCELLULAR CARCINOMA 1340 0.2435
9 CRYOGLOBULINAEMIA 96 0.2043
See all enriched reactions for Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]